Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10 years and future perspectives.

Valent P, Hadzijusufovic E, Grunt T, Karlic H, Peter B, Herrmann H, Eisenwort G, Hoermann G, Schulenburg A, Willmann M, Hubmann R, Shehata M, Selzer E, Gleixner KV, Rülicke T, Sperr WR, Marian B, Pfeilstöcker M, Pehamberger H, Keil F, Jäger U, Zielinski C.

Wien Klin Wochenschr. 2018 Jul 13. doi: 10.1007/s00508-018-1355-7. [Epub ahead of print] Review.

PMID:
30006759
2.

Minimal-invasive temporary gastric stimulation: A pilot study to predict the outcome of electronic gastric stimulation with the Enterra™ system.

Corvinus FM, Heinrich S, Neumann H, Hadzijusufovic E, Babic B, Lang H, Grimminger PP.

Dig Liver Dis. 2018 Jun 7. pii: S1590-8658(18)30767-9. doi: 10.1016/j.dld.2018.05.023. [Epub ahead of print]

PMID:
29970295
3.

Novel multi-image view for neuromapping meets the needs of the robotic surgeon.

Schiemer JF, Zimniak L, Hadzijusufovic E, Lang H, Kneist W.

Tech Coloproctol. 2018 Jun;22(6):445-448. doi: 10.1007/s10151-018-1804-3. Epub 2018 Jun 4.

PMID:
29868993
4.

The da Vinci Xi Robotic Four-Arm Approach for Robotic-Assisted Minimally Invasive Esophagectomy.

Grimminger PP, Hadzijusufovic E, Ruurda JP, Lang H, van Hillegersberg R.

Thorac Cardiovasc Surg. 2018 Aug;66(5):407-409. doi: 10.1055/s-0038-1636933. Epub 2018 Apr 6.

PMID:
29625500
5.

The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis.

Schneeweiss M, Peter B, Bibi S, Eisenwort G, Smiljkovic D, Blatt K, Jawhar M, Berger D, Stefanzl G, Herndlhofer S, Greiner G, Hoermann G, Hadzijusufovic E, Gleixner KV, Bettelheim P, Geissler K, Sperr WR, Reiter A, Arock M, Valent P.

Haematologica. 2018 May;103(5):799-809. doi: 10.3324/haematol.2017.179895. Epub 2018 Feb 8.

6.

Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells.

Peter B, Bibi S, Eisenwort G, Wingelhofer B, Berger D, Stefanzl G, Blatt K, Herrmann H, Hadzijusufovic E, Hoermann G, Hoffmann T, Schwaab J, Jawhar M, Willmann M, Sperr WR, Zuber J, Sotlar K, Horny HP, Moriggl R, Reiter A, Arock M, Valent P.

Leukemia. 2018 Apr;32(4):1016-1022. doi: 10.1038/leu.2017.338. Epub 2017 Nov 29.

7.

Evaluation of cooperative antileukemic effects of nilotinib and vildagliptin in Ph+ chronic myeloid leukemia.

Willmann M, Sadovnik I, Eisenwort G, Entner M, Bernthaler T, Stefanzl G, Hadzijusufovic E, Berger D, Herrmann H, Hoermann G, Valent P, Rülicke T.

Exp Hematol. 2018 Jan;57:50-59.e6. doi: 10.1016/j.exphem.2017.09.012. Epub 2017 Oct 12.

PMID:
29031704
8.

Robotic-Assisted Ivor Lewis Esophagectomy (RAMIE) with a Standardized Intrathoracic Circular End-to-side Stapled Anastomosis and a Team of Two (Surgeon and Assistant Only).

Grimminger PP, Hadzijusufovic E, Lang H.

Thorac Cardiovasc Surg. 2018 Aug;66(5):404-406. doi: 10.1055/s-0037-1606198. Epub 2017 Sep 4.

PMID:
28869991
9.

Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site.

Hadzijusufovic E, Albrecht-Schgoer K, Huber K, Hoermann G, Grebien F, Eisenwort G, Schgoer W, Herndlhofer S, Kaun C, Theurl M, Sperr WR, Rix U, Sadovnik I, Jilma B, Schernthaner GH, Wojta J, Wolf D, Superti-Furga G, Kirchmair R, Valent P.

Leukemia. 2017 Nov;31(11):2388-2397. doi: 10.1038/leu.2017.245. Epub 2017 Jul 31.

10.

Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML.

Valent P, Hadzijusufovic E, Hoermann G, Füreder W, Schernthaner GH, Sperr WR, Kirchmair R, Wolf D.

Leuk Res. 2017 Aug;59:47-54. doi: 10.1016/j.leukres.2017.05.008. Epub 2017 May 12. Review.

PMID:
28549238
11.

TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML.

Valent P, Herndlhofer S, Schneeweiß M, Boidol B, Ringler A, Kubicek S, Gleixner KV, Hoermann G, Hadzijusufovic E, Müllauer L, Sperr WR, Superti-Furga G, Mannhalter C.

Oncotarget. 2017 Apr 4;8(14):23061-23072. doi: 10.18632/oncotarget.15481.

12.

The JAK2/STAT5 signaling pathway as a potential therapeutic target in canine mastocytoma.

Keller A, Wingelhofer B, Peter B, Bauer K, Berger D, Gamperl S, Reifinger M, Cerny-Reiterer S, Moriggl R, Willmann M, Valent P, Hadzijusufovic E.

Vet Comp Oncol. 2018 Mar;16(1):55-68. doi: 10.1111/vco.12311. Epub 2017 Apr 11.

13.

Achalasia-an unnecessary long way to diagnosis.

Niebisch S, Hadzijusufovic E, Mehdorn M, Müller M, Scheuermann U, Lyros O, Schulz HG, Jansen-Winkeln B, Lang H, Gockel I.

Dis Esophagus. 2017 May 1;30(5):1-6. doi: 10.1093/dote/dow004.

PMID:
28375437
14.

Proposed diagnostic criteria and classification of basophilic leukemias and related disorders.

Valent P, Sotlar K, Blatt K, Hartmann K, Reiter A, Sadovnik I, Sperr WR, Bettelheim P, Akin C, Bauer K, George TI, Hadzijusufovic E, Wolf D, Gotlib J, Mahon FX, Metcalfe DD, Horny HP, Arock M.

Leukemia. 2017 Apr;31(4):788-797. doi: 10.1038/leu.2017.15. Epub 2017 Jan 16. Review.

PMID:
28090091
15.

IL-4 downregulates expression of the target receptor CD30 in neoplastic canine mast cells.

Bauer K, Hadzijusufovic E, Cerny-Reiterer S, Hoermann G, Reifinger M, Pirker A, Valent P, Willmann M.

Vet Comp Oncol. 2017 Dec;15(4):1240-1256. doi: 10.1111/vco.12260. Epub 2016 Aug 9.

16.

Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis.

Blatt K, Cerny-Reiterer S, Schwaab J, Sotlar K, Eisenwort G, Stefanzl G, Hoermann G, Mayerhofer M, Schneeweiss M, Knapp S, Rülicke T, Hadzijusufovic E, Bauer K, Smiljkovic D, Willmann M, Reiter A, Horny HP, Valent P.

Blood. 2015 Dec 24;126(26):2832-41. doi: 10.1182/blood-2015-03-637728. Epub 2015 Oct 20. Erratum in: Blood. 2018 Mar 22;131(12 ):1390.

17.

Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth.

Peter B, Winter GE, Blatt K, Bennett KL, Stefanzl G, Rix U, Eisenwort G, Hadzijusufovic E, Gridling M, Dutreix C, Hoermann G, Schwaab J, Radia D, Roesel J, Manley PW, Reiter A, Superti-Furga G, Valent P.

Leukemia. 2016 Feb;30(2):464-72. doi: 10.1038/leu.2015.242. Epub 2015 Sep 9.

18.

Identification of bromodomain-containing protein-4 as a novel marker and epigenetic target in mast cell leukemia.

Wedeh G, Cerny-Reiterer S, Eisenwort G, Herrmann H, Blatt K, Hadzijusufovic E, Sadovnik I, Müllauer L, Schwaab J, Hoffmann T, Bradner JE, Radia D, Sperr WR, Hoermann G, Reiter A, Horny HP, Zuber J, Arock M, Valent P.

Leukemia. 2015 Nov;29(11):2230-7. doi: 10.1038/leu.2015.138. Epub 2015 Jun 9.

19.

Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors.

Valent P, Hadzijusufovic E, Schernthaner GH, Wolf D, Rea D, le Coutre P.

Blood. 2015 Feb 5;125(6):901-6. doi: 10.1182/blood-2014-09-594432. Epub 2014 Dec 18.

20.

The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease.

Hoermann G, Gleixner KV, Dinu GE, Kundi M, Greiner G, Wimazal F, Hadzijusufovic E, Mitterbauer G, Mannhalter C, Valent P, Sperr WR.

Allergy. 2014 Jun;69(6):810-3. doi: 10.1111/all.12409. Epub 2014 Apr 17.

21.

Identification of heat shock protein 32 (Hsp32) as a novel target in acute lymphoblastic leukemia.

Cerny-Reiterer S, Meyer RA, Herrmann H, Peter B, Gleixner KV, Stefanzl G, Hadzijusufovic E, Pickl WF, Sperr WR, Melo JV, Maeda H, Jäger U, Valent P.

Oncotarget. 2014 Mar 15;5(5):1198-211.

22.

A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection.

Saleh R, Wedeh G, Herrmann H, Bibi S, Cerny-Reiterer S, Sadovnik I, Blatt K, Hadzijusufovic E, Jeanningros S, Blanc C, Legarff-Tavernier M, Chapiro E, Nguyen-Khac F, Subra F, Bonnemye P, Dubreuil P, Desplat V, Merle-Béral H, Willmann M, Rülicke T, Valent P, Arock M.

Blood. 2014 Jul 3;124(1):111-20. doi: 10.1182/blood-2013-10-534685. Epub 2014 Mar 27.

23.

Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy.

Bibi S, Arslanhan MD, Langenfeld F, Jeanningros S, Cerny-Reiterer S, Hadzijusufovic E, Tchertanov L, Moriggl R, Valent P, Arock M.

Haematologica. 2014 Mar;99(3):417-29. doi: 10.3324/haematol.2013.098442. Review.

24.

Phenotyping of human melanoma cells reveals a unique composition of receptor targets and a subpopulation co-expressing ErbB4, EPO-R and NGF-R.

Mirkina I, Hadzijusufovic E, Krepler C, Mikula M, Mechtcheriakova D, Strommer S, Stella A, Jensen-Jarolim E, Höller C, Wacheck V, Pehamberger H, Valent P.

PLoS One. 2014 Jan 29;9(1):e84417. doi: 10.1371/journal.pone.0084417. eCollection 2014.

25.

The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells.

Peter B, Cerny-Reiterer S, Hadzijusufovic E, Schuch K, Stefanzl G, Eisenwort G, Gleixner KV, Hoermann G, Mayerhofer M, Kundi M, Baumgartner S, Sperr WR, Pickl WF, Willmann M, Valent P.

J Leukoc Biol. 2014 Jan;95(1):95-104. doi: 10.1189/jlb.1112609. Epub 2013 Sep 19.

PMID:
24052572
26.

Guidelines and diagnostic algorithm for patients with suspected systemic mastocytosis: a proposal of the Austrian competence network (AUCNM).

Valent P, Aberer E, Beham-Schmid C, Fellinger C, Fuchs W, Gleixner KV, Greul R, Hadzijusufovic E, Hoermann G, Sperr WR, Wimazal F, Wöhrl S, Zahel B, Pehamberger H.

Am J Blood Res. 2013 May 5;3(2):174-80. Print 2013.

27.

Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V.

Gleixner KV, Peter B, Blatt K, Suppan V, Reiter A, Radia D, Hadzijusufovic E, Valent P.

Haematologica. 2013 Sep;98(9):1450-7. doi: 10.3324/haematol.2012.079202. Epub 2013 Mar 28.

28.

European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives.

Valent P, Arock M, Bonadonna P, Brockow K, Broesby-Olsen S, Escribano L, Gleixner KV, Grattan C, Hadzijusufovic E, Hägglund H, Hermine O, Horny HP, Kluin-Nelemans HC, Maurer M, Niedoszytko M, Nedoszytko B, Nilsson G, Oude-Elberink HN, Orfao A, Radia D, Reiter A, Siebenhaar F, Sotlar K, Sperr WR, Triggiani M, VanDoormaal JJ, Várkonyi J, Yavuz S, Hartmann K.

Wien Klin Wochenschr. 2012 Dec;124(23-24):807-14. doi: 10.1007/s00508-012-0293-z. Epub 2012 Nov 20. Review.

PMID:
23179435
29.

NI-1: a novel canine mastocytoma model for studying drug resistance and IgER-dependent mast cell activation.

Hadzijusufovic E, Peter B, Herrmann H, Rülicke T, Cerny-Reiterer S, Schuch K, Kenner L, Thaiwong T, Yuzbasiyan-Gurkan V, Pickl WF, Willmann M, Valent P.

Allergy. 2012 Jul;67(7):858-68. doi: 10.1111/j.1398-9995.2012.02833.x. Epub 2012 May 15.

30.

5-azacytidine and decitabine exert proapoptotic effects on neoplastic mast cells: role of FAS-demethylation and FAS re-expression, and synergism with FAS-ligand.

Ghanim V, Herrmann H, Heller G, Peter B, Hadzijusufovic E, Blatt K, Schuch K, Cerny-Reiterer S, Mirkina I, Karlic H, Pickl WF, Zöchbauer-Müller S, Valent P.

Blood. 2012 May 3;119(18):4242-52. doi: 10.1182/blood-2011-09-382770. Epub 2012 Mar 21.

31.

The PI3-kinase/mTOR-targeting drug NVP-BEZ235 inhibits growth and IgE-dependent activation of human mast cells and basophils.

Blatt K, Herrmann H, Mirkina I, Hadzijusufovic E, Peter B, Strommer S, Hoermann G, Mayerhofer M, Hoetzenecker K, Klepetko W, Ghanim V, Marth K, Füreder T, Wacheck V, Valenta R, Valent P.

PLoS One. 2012;7(1):e29925. doi: 10.1371/journal.pone.0029925. Epub 2012 Jan 27.

32.

KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib.

Gleixner KV, Mayerhofer M, Cerny-Reiterer S, Hörmann G, Rix U, Bennett KL, Hadzijusufovic E, Meyer RA, Pickl WF, Gotlib J, Horny HP, Reiter A, Mitterbauer-Hohendanner G, Superti-Furga G, Valent P.

Blood. 2011 Aug 18;118(7):1885-98. doi: 10.1182/blood-2010-06-289959. Epub 2011 Jun 16.

33.

Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536.

Peter B, Gleixner KV, Cerny-Reiterer S, Herrmann H, Winter V, Hadzijusufovic E, Ferenc V, Schuch K, Mirkina I, Horny HP, Pickl WF, Müllauer L, Willmann M, Valent P.

Haematologica. 2011 May;96(5):672-80. doi: 10.3324/haematol.2010.031328. Epub 2011 Jan 17.

34.

KIT polymorphisms and mutations determine responses of neoplastic mast cells to bafetinib (INNO-406).

Peter B, Hadzijusufovic E, Blatt K, Gleixner KV, Pickl WF, Thaiwong T, Yuzbasiyan-Gurkan V, Willmann M, Valent P.

Exp Hematol. 2010 Sep;38(9):782-91. doi: 10.1016/j.exphem.2010.05.004. Epub 2010 May 26.

PMID:
20685234
35.

H1-receptor antagonists terfenadine and loratadine inhibit spontaneous growth of neoplastic mast cells.

Hadzijusufovic E, Peter B, Gleixner KV, Schuch K, Pickl WF, Thaiwong T, Yuzbasiyan-Gurkan V, Mirkina I, Willmann M, Valent P.

Exp Hematol. 2010 Oct;38(10):896-907. doi: 10.1016/j.exphem.2010.05.008. Epub 2010 Jun 1.

36.

Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.

Gleixner KV, Ferenc V, Peter B, Gruze A, Meyer RA, Hadzijusufovic E, Cerny-Reiterer S, Mayerhofer M, Pickl WF, Sillaber C, Valent P.

Cancer Res. 2010 Feb 15;70(4):1513-23. doi: 10.1158/0008-5472.CAN-09-2181. Epub 2010 Feb 9.

37.

Chemotherapy in canine acute megakaryoblastic leukemia: a case report and review of the literature.

Willmann M, Müllauer L, Schwendenwein I, Wolfesberger B, Kleiter M, Pagitz M, Hadzijusufovic E, Shibly S, Reifinger M, Thalhammer JG, Valent P.

In Vivo. 2009 Nov-Dec;23(6):911-8.

38.

Targeting of Hsp32 in solid tumors and leukemias: a novel approach to optimize anticancer therapy.

Gleixner KV, Mayerhofer M, Vales A, Gruze A, Hörmann G, Cerny-Reiterer S, Lackner E, Hadzijusufovic E, Herrmann H, Iyer AK, Krauth MT, Pickl WF, Marian B, Panzer-Grümayer R, Sillaber C, Maeda H, Zielinski C, Valent P.

Curr Cancer Drug Targets. 2009 Aug;9(5):675-89. Epub 2009 Aug 1.

PMID:
19508170
39.

Growth-inhibitory effects of four tyrosine kinase inhibitors on neoplastic feline mast cells exhibiting a Kit exon 8 ITD mutation.

Hadzijusufovic E, Peter B, Rebuzzi L, Baumgartner C, Gleixner KV, Gruze A, Thaiwong T, Pickl WF, Yuzbasiyan-Gurkan V, Willmann M, Valent P.

Vet Immunol Immunopathol. 2009 Dec 15;132(2-4):243-50. doi: 10.1016/j.vetimm.2009.05.007. Epub 2009 May 18.

PMID:
19505729
40.

Targeting of heat-shock protein 32/heme oxygenase-1 in canine mastocytoma cells is associated with reduced growth and induction of apoptosis.

Hadzijusufovic E, Rebuzzi L, Gleixner KV, Ferenc V, Peter B, Kondo R, Gruze A, Kneidinger M, Krauth MT, Mayerhofer M, Samorapoompichit P, Greish K, Iyer AK, Pickl WF, Maeda H, Willmann M, Valent P.

Exp Hematol. 2008 Nov;36(11):1461-70. doi: 10.1016/j.exphem.2008.06.002. Epub 2008 Aug 23.

PMID:
18723263
41.

Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells.

Gleixner KV, Rebuzzi L, Mayerhofer M, Gruze A, Hadzijusufovic E, Sonneck K, Vales A, Kneidinger M, Samorapoompichit P, Thaiwong T, Pickl WF, Yuzbasiyan-Gurkan V, Sillaber C, Willmann M, Valent P.

Exp Hematol. 2007 Oct;35(10):1510-21. Epub 2007 Aug 2.

PMID:
17681669

Supplemental Content

Loading ...
Support Center